Archive | February, 2013

MO Money Hair Trigger-ISRG Down 11% on FDA Probe Report

Market Reverses Late in the Day Giving Pause to Euphoria Intuitive Surgical (ISRG $509.89) plunged 11% in final minutes upon disclosure from Bloomberg of  a safety probe from U.S. regulators. An FDA survey is trying to determine “whether adverse incident reports sent to the agency are ‘a true reflection of problems’.” The trading volume of 783,200 […]

Continue Reading 0

Rayno Biopharmaceutical Portfolio Performance- After Sell-Off 2/26/13

 Caution-Follow Technicals-Potential for Macro Risk Off The Life Science sector is about 2% off highs of February 1 and has formed a double top from October 5 highs. In recent posts we urged caution as some MO stocks had blow-off tops (ALXN,MDVN, REGN) and the IBB and XBI were unable to reach new highs with […]

Continue Reading 0

Rayno Life Science Tools and DX: Genomic Health (GHDX $28.80) Added

Genomic Health-Good Long Term Value This looks like a good entry point for buying shares of Genomic Health (GHDX $28.50), a molecular diagnostic company focused on personalized medicine for cancer with its oncotype DX invasive breast cancer test.Yesterday the Company announced results from next generation sequencing studies from paraffin tissue (FPET) to improve the precision […]

Continue Reading 0

Biotech Stocks Rally After Brief Sell-Off: INFI, PCYC Update-1 2/25

Technicals Still Rule As Momentum Eases-Reiterate Caution MO favs down:  INFI, MDVN, PCYC The Life Science sector is up about 1% after two days of selling on heavy volume. The bellwether ETFs (IBB $145.16)  are about 2% off 52 week highs and we do not expect this rally to surpass highs so caution is still […]

Continue Reading 0

MO Money Moves On to Infinity Pharmaceuticals (INFI $41.10)Up 16%

The BIG money in biotech has moved on to new names like Infinity (INFI) up 15 points since December. In the meantime they are moving out of the big winners from 2012 like Alexion (ALXN  $83.4) down 3% and Regeneron (REGN $160) down 2.7% . See previous postings. The tremendous liquidity in this market can […]

Continue Reading 0

Big Money and Celebrity Financial News: Icahn Effect Redux

 The Stock Market Realty Shows In case you missed it stocks lately are being driven by hedge funds and celebrity billionaires who tout their positions. The Icahn vs Ackman drama is the latest high profile realty show featured mainly by CNBC-TV. Biotechnology stocks have always been driven by  a BIG money following and we covered an […]

Continue Reading 0

Rayno Biopharmaceutical Focus Stocks: Ones to Watch -ALXN,PCYC,REGN

Caution is Warranted by Technicals Given the toppiness in the biotechnology sector and the stalling of the IBB ($146), it looks like momentum is waning and some MO stocks favored by BIG money are selling off. Nonetheless we have not made any portfolio recommendations other than raising a little cash. We will update if there is […]

Continue Reading 0

Sierra SnowBlog: No Big Storms on Horizon for February Update 2/25

Feb. 25 Update No Snow for 8-10 Days Drought article: Thin Snowpack Signals Summer of Fire and Drought – NYTimes.com Snow on the Way -Maybe 12-18 in (Only 8 in.) Storm track variable with ppt levels down a tad. Tuesday still looks good in the Sierras then storm moves South and East with blizzard conditions in […]

Continue Reading 0

Market Grinds Up- With Profit Taking In Some Biotech MO Stocks

Sell-Off Evident In Big Winners-Technicals Are Very Important In Here The 2013 rally trickled up today with the DOW and S&P up, but off its highs. NASDAQ is flat. The media trash talk has stoked up with many well known pundits and strategists urging caution but others repeating the worn mantra “don’t fight the tape, […]

Continue Reading 0

Life Science Stocks Look Toppy: Red Screen Today ALXN,IBB,REGN Update 1

Raise a Little Cash as Macro Focus Brings Choppy Action Life Science stocks took a hit today underperforming NASDAQ which was down only 3.35 pts. The biotech sector has been pretty much on a tear since the November bottom as they re-accelerated in mid-December. The biotech ETF (IBB) shows a double top from October and […]

Continue Reading 0